Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

Separately, EF Hutton Acquisition Co. I raised Anixa Biosciences to a “strong-buy” rating in a research note on Wednesday, August 7th.

Anixa Biosciences Stock Up 0.5 %

Shares of ANIX stock opened at $3.06 on Tuesday. The firm has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $2.99. The company has a market capitalization of $98.47 million, a PE ratio of -7.85 and a beta of 0.84. Anixa Biosciences has a 12-month low of $2.14 and a 12-month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Friday, September 6th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. As a group, research analysts expect that Anixa Biosciences will post -0.42 EPS for the current year.

Institutional Trading of Anixa Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Virtu Financial LLC raised its position in Anixa Biosciences by 47.2% in the 1st quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock worth $50,000 after purchasing an additional 5,183 shares during the period. Nations Financial Group Inc. IA ADV increased its position in shares of Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after acquiring an additional 7,500 shares during the period. Concorde Asset Management LLC purchased a new position in shares of Anixa Biosciences in the second quarter valued at about $31,000. International Assets Investment Management LLC increased its position in shares of Anixa Biosciences by 170.0% in the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock valued at $1,190,000 after acquiring an additional 23,800 shares during the period. Finally, Tyler Stone Wealth Management increased its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.